Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on urothelial cancer from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Thomas Powles comments on practice changing results in the management of urothelial cancer and new biomarker data for improved patients selection.

He first talks about the effect on the risk of death of starting maintenance immunotherapy right after chemotherapy in patients with advanced urothelial cancer, that was demonstrated in the JAVELIN 100 trial. These practice changing results in the front line setting were validated in broad subgroups of patients.

Secondly he discusses the interesting results from the DUTRENEO study, evaluating pathologic complete response to immunotherapy combination vs chemotherapy in patients with muscle-invasive urothelial bladder cancer, selected according to interferon-gamma immune signature.

Finally he looks in the results from the exploratory analysis of biomarkers data from the IMvigor130 trial testing the Immunotherapy vs immunotherapy combination with chemotherapy vs chemotherapy alone in metastatic urothelial cancer. He focuses on the promising results presented in the PD-L1, TMB and combined biomarkers subgroups of patients.

Abstracts:

  • LBA1: Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis - Thomas Powles
  • 5012: DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature - Enrique Grande
  • 5011: Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study – Matthew Galsky

This video is part of the Genitourinary Cancers track 2020, supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.